XML 83 R35.htm IDEA: XBRL DOCUMENT
v3.20.1

Segments (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2020
Summary of Segment Profit | a. Segment information:
|  | Three months ended March 31, |
|  | 2020 |
|  | North America |  |  | Europe |  |  | International Markets |
|  | (U.S. $ in millions) |
Revenues |  | $ | 2,082 |  |  | $ | 1,402 |  |  | $ | 565 |
Gross profit |  |  | 1,062 |  |  |  | 823 |  |  |  | 305 |
R&D expenses |  |  | 146 |  |  |  | 55 |  |  |  | 15 |
S&M expenses |  |  | 251 |  |  |  | 202 |  |  |  | 106 |
G&A expenses |  |  | 118 |  |  |  | 66 |  |  |  | 34 |
Other income |  |  | (2 | ) |  |  | (1 | ) |  |  | (6 | )
Segment profit |  | $ | 550 |  |  | $ | 502 |  |  | $ | 156 |
|  | Three months ended March 31, |
|  | 2019 |
|  | North America |  |  | Europe |  |  | International Markets * |
|  | (U.S. $ in millions) |
Revenues |  | $ | 2,047 |  |  | $ | 1,264 |  |  | $ | 521 |
Gross profit |  |  | 1,039 |  |  |  | 730 |  |  |  | 269 |
R&D expenses |  |  | 165 |  |  |  | 66 |  |  |  | 22 |
S&M expenses |  |  | 268 |  |  |  | 215 |  |  |  | 115 |
G&A expenses |  |  | 112 |  |  |  | 48 |  |  |  | 36 |
Other (income) expense |  |  | (4 | ) |  |  | (1 | ) |  |  | — |
Segment profit |  | $ | 498 |  |  | $ | 403 |  |  | $ | 97 |
* | The data presented for prior periods have been revised to reflect a revision in the presentation of net revenues and cost of sales in the consolidated financial statements. See note 1c for additional information.
Schedule Of Consolidated Income Before Income Tax |
|  | Three months ended March 31, |
|  | 2020 |  |  | 2019 |
|  | (U.S. $ in millions) |
North America profit |  | $ | 550 |  |  | $ | 498 |
Europe profit |  |  | 502 |  |  |  | 403 |
International Markets profit |  |  | 156 |  |  |  | 97 |
Total reportable segments profit |  |  | 1,208 |  |  |  | 998 |
Profit of other activities |  |  | 36 |  |  |  | 21 |
Total segments profit |  |  | 1,244 |  |  |  | 1,019 |
Amounts not allocated to segments: |  |  |  |  |  |  |  |
Amortization |  |  | 258 |  |  |  | 283 |
Other assets impairments, restructuring and other items |  |  | 121 |  |  |  | 1 |
Intangible asset impairments |  |  | 649 |  |  |  | 469 |
Legal settlements and loss contingencies |  |  | (25 | ) |  |  | 57 |
Other unallocated amounts |  |  | 49 |  |  |  | 75 |
Consolidated operating income (loss) |  |  | 191 |  |  |  | 134 |
Financial expenses, net |  |  | 224 |  |  |  | 218 |
Consolidated income (loss) before income taxes |  | $ | (33 | ) |  | $ | (84 | )
Schedule of Net Sales by Product Line | The following tables present revenues by major products and activities for the three months ended March 31, 2020 and 2019:
North America |  | Three months ended March 31, |
|  | 2020 |  |  | 2019 |
|  | (U.S. $ in millions) |
Generic products |  | $ | 952 |  |  | $ | 966 |
AJOVY |  |  | 29 |  |  |  | 20 |
AUSTEDO |  |  | 122 |  |  |  | 74 |
BENDEKA/TREANDA |  |  | 105 |  |  |  | 122 |
COPAXONE |  |  | 198 |  |  |  | 208 |
ProAir* |  |  | 59 |  |  |  | 59 |
QVAR |  |  | 45 |  |  |  | 64 |
Anda |  |  | 426 |  |  |  | 379 |
Other |  |  | 146 |  |  |  | 155 |
Total |  | $ | 2,082 |  |  | $ | 2,047 |
* | Does not include revenues from the ProAir authorized generic, which are included under generic products.
Europe |  | Three months ended March 31, |
|  | 2020 |  |  | 2019 |
|  | (U.S. $ in millions) |
Generic products |  | $ | 1,032 |  |  | $ | 919 |
COPAXONE |  |  | 109 |  |  |  | 114 |
Respiratory products |  |  | 106 |  |  |  | 91 |
AJOVY |  |  | 4 |  |  |  | — |
Other |  |  | 151 |  |  |  | 140 |
Total |  | $ | 1,402 |  |  | $ | 1,264 |
International markets * |  | Three months ended March 31, |
|  | 2020 |  |  | 2019 |
|  | (U.S. $ in millions) |
Generic products |  | $ | 449 |  |  | $ | 441 |
COPAXONE |  |  | 12 |  |  |  | 13 |
Other |  |  | 104 |  |  |  | 67 |
Total |  | $ | 565 |  |  | $ | 521 |
* | The data presented for prior periods have been revised to reflect a revision in the presentation of net revenues and cost of sales in the consolidated financial statements. See note 1c for additional information.

X
- Definition Schedule of consolidated income before income tax. + References No definition available. + Details
Name: | teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock
Namespace Prefix: | teva_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8924-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599 + Details
Name: | us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599 + Details
Name: | us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration